125 related articles for article (PubMed ID: 31582618)
1. [Effects of Renal Function Evaluation with or without Serum Creatinine Adjustment on Cisplatin/Fluorouracil Therapy for Cervical Cancer].
Takagi M; Sagara A; Ishizawa A; Ito A; Miyazaki M; Senzaki K; Nagai T; Yamada K
Yakugaku Zasshi; 2019; 139(10):1327-1332. PubMed ID: 31582618
[TBL] [Abstract][Full Text] [Related]
2. Validity of new methods to evaluate renal function in cancer patients treated with cisplatin.
Funakoshi Y; Fujiwara Y; Kiyota N; Mukohara T; Shimada T; Toyoda M; Imamura Y; Chayahara N; Tomioka H; Umezu M; Otsuki N; Nibu K; Minami H
Cancer Chemother Pharmacol; 2016 Feb; 77(2):281-8. PubMed ID: 26791871
[TBL] [Abstract][Full Text] [Related]
3. Serial-measured versus estimated creatinine clearance in patients with non-small cell lung cancer receiving cisplatin-based chemotherapy.
Chang GC; Yang TY; Shih CM; Lin LY; Lee HS; Chiang CD
J Formos Med Assoc; 2003 Apr; 102(4):257-61. PubMed ID: 12833190
[TBL] [Abstract][Full Text] [Related]
4. Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients.
Ishitsuka R; Miyazaki J; Ichioka D; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Kawai K; Nishiyama H
Clin Exp Nephrol; 2017 Aug; 21(4):732-740. PubMed ID: 27565169
[TBL] [Abstract][Full Text] [Related]
5. Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study.
Oka T; Kimura T; Suzumura T; Yoshimoto N; Nakai T; Yamamoto N; Matsuura K; Mitsuoka S; Yoshimura N; Kudoh S; Hirata K
BMC Pharmacol Toxicol; 2014 Dec; 15():70. PubMed ID: 25472655
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of renal function using the level of neutrophil gelatinase-associated lipocalin is not predictive of nephrotoxicity associated with cisplatin-based chemotherapy.
Kos FT; Sendur MA; Aksoy S; Celik HT; Sezer S; Civelek B; Yaman S; Zengin N
Asian Pac J Cancer Prev; 2013; 14(2):1111-4. PubMed ID: 23621196
[TBL] [Abstract][Full Text] [Related]
7. [Change of creatinine clearance rate in accordance with aging in Japanese patients with head and neck cancer].
Nishimura G; Horiuchi C; Yoshida T; Kawakami M; Yabuki K; Taguchi T; Nagao J; Kondo N; Masuda Y; Matsuda H; Mikami Y; Tsukuda M
Gan To Kagaku Ryoho; 2006 Apr; 33(4):463-6. PubMed ID: 16612154
[TBL] [Abstract][Full Text] [Related]
8. Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
Ahn JH; Kang YK; Kim TW; Bahng H; Chang HM; Kang WC; Kim WK; Lee JS; Park JS
Cancer Chemother Pharmacol; 2002 Aug; 50(2):104-10. PubMed ID: 12172973
[TBL] [Abstract][Full Text] [Related]
9. Renal toxicity of adjuvant chemoradiotherapy with cisplatin in gastric cancer.
Welz S; Hehr T; Kollmannsberger C; Bokemeyer C; Belka C; Budach W
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1429-35. PubMed ID: 17692474
[TBL] [Abstract][Full Text] [Related]
10. Comparison of methods of assessment of renal function in patients with cancer treated with cisplatin, carboplatin or methotrexate.
Robinson BA; Frampton CM; Colls BM; Atkinson CH; Fitzharris BM
Aust N Z J Med; 1990 Oct; 20(5):657-62. PubMed ID: 2285382
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of two different chemotherapy regimens for concurrent chemoradiotherapy in stage Ib2 to IVa squamous cell carcinoma of the uterine cervix].
Li XF; Li YH; Gao YN; Li CL; Yue HZ; Xu G; Li DM; Su X
Zhonghua Fu Chan Ke Za Zhi; 2013 Oct; 48(10):763-7. PubMed ID: 24406134
[TBL] [Abstract][Full Text] [Related]
12. [Effects of urinastatin against nephrotoxicity of cisplatinum].
Arakawa A; Kato N; Asai H; Yasui Y; Suzumori K; Suzumori K; Yagami Y
Gan To Kagaku Ryoho; 1990 Nov; 17(11):2229-34. PubMed ID: 2241187
[TBL] [Abstract][Full Text] [Related]
13. [Serum creatinine and creatinine clearance to estimate renal function in essential hypertension].
Jabary NS; Martín D; Muñoz MF; Santos M; Herruzo J; Gordillo R; Bustamante J
Nefrologia; 2006; 26(1):64-73. PubMed ID: 16649427
[TBL] [Abstract][Full Text] [Related]
14. Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone.
Merouani A; Davidson SA; Schrier RW
Am J Nephrol; 1997; 17(1):53-8. PubMed ID: 9057954
[TBL] [Abstract][Full Text] [Related]
15. [Retrospective study of chemoradiotherapy based on cisplatin compared with radiotherapy alone for cervical cancer].
Han C; Kong WM
Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):723-6. PubMed ID: 18307894
[TBL] [Abstract][Full Text] [Related]
16. Plasma ghrelin levels as a predictor of adverse renal events due to cisplatin-based chemotherapy in patients with esophageal cancer.
Yanagimoto Y; Takiguchi S; Miyazaki Y; Makino T; Takahashi T; Kurokawa Y; Yamasaki M; Miyata H; Nakajima K; Mori M; Doki Y
Jpn J Clin Oncol; 2016 May; 46(5):421-6. PubMed ID: 26839323
[TBL] [Abstract][Full Text] [Related]
17. Estimated creatinine clearance instead of plasma creatinine level as prognostic test for postoperative renal function in patients undergoing coronary artery bypass surgery.
Noyez L; Plesiewicz I; Verheugt FW
Eur J Cardiothorac Surg; 2006 Apr; 29(4):461-5. PubMed ID: 16483789
[TBL] [Abstract][Full Text] [Related]
18. [Effects of fractionated low dose Cisplatin on renal functions of patients with gastric carcinoma].
Li Y; Shen L; Li J; Jin ML
Ai Zheng; 2007 Dec; 26(12):1354-6. PubMed ID: 18076800
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and renal toxicity of cisplatin in cancer patients with renal dysfunction.
Morita-Ogawa T; Sugita H; Minami H; Yamaguchi T; Hanada K
Cancer Chemother Pharmacol; 2020 Oct; 86(4):559-566. PubMed ID: 32949266
[TBL] [Abstract][Full Text] [Related]
20. Dose adjustment of cisplatin, etoposide, and ifosfamide according to kidney function: a retrospective analysis and implications for medication safety.
Grafe C; Semrau S; Hein A; Beckmann MW; Mackensen A; Dörje F; Fromm MF
Naunyn Schmiedebergs Arch Pharmacol; 2018 Feb; 391(2):219-229. PubMed ID: 29294142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
